MENU
JDOC
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

JDOC stock forecast, quote, news & analysis

The investment seeks to provide long-term capital appreciation... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
JDOC
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for JDOC with price predictions
Oct 22, 2026

JDOC in upward trend: price rose above 50-day moving average on October 15, 2026

JDOC moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 16 of 19 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on JDOC as a result. In 35 of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for JDOC just turned positive on October 12, 2026. Looking at past instances where JDOC's MACD turned positive, the stock continued to rise in 24 of 29 cases over the following month. The odds of a continued upward trend are 83%.

The 10-day moving average for JDOC crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 6 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

Following a +1.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where JDOC advanced for three days, in 91 of 121 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JDOC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

JDOC broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for JDOC entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Bristol-Myers Squibb Co (NYSE:BMY), Medtronic plc (NYSE:MDT), Regeneron Pharmaceuticals (NASDAQ:REGN).

Industry description

The investment seeks to provide long-term capital appreciation. The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.

Market Cap

The average market capitalization across the JPMorgan Healthcare Leaders ETF (JDOC) ETF is 108.01B. The market cap for tickers in the group ranges from 771.42M to 1.13T. LLY holds the highest valuation in this group at 1.13T. The lowest valued company is APMD at 771.42M.

High and low price notable news

The average weekly price growth across all stocks in the JPMorgan Healthcare Leaders ETF (JDOC) ETF was 3%. For the same ETF, the average monthly price growth was 4%, and the average quarterly price growth was 17%. IRON experienced the highest price growth at 32%, while RCUS experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the JPMorgan Healthcare Leaders ETF (JDOC) ETF was -9%. For the same stocks of the ETF, the average monthly volume growth was 22% and the average quarterly volume growth was 16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 46
Price Growth Rating: 39
SMR Rating: 63
Profit Risk Rating: 66
Seasonality Score: 20 (-100 ... +100)
JDOC in upward trend: price rose above 50-day moving average on October 15, 2026